Beta Bionics (BBNX) Liabilities and Shareholders Equity (2023 - 2026)

Beta Bionics' Liabilities and Shareholders Equity history runs 4 years deep, the most recent figure standing at $304.4 million for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity fell 9.94% year-over-year to $304.4 million; the TTM figure through Mar 2026 stood at $1.3 billion (up 165.18% YoY), while the FY2025 annual figure was $328.7 million, up 119.68% from the prior year.
• Liabilities and Shareholders Equity came in at $304.4 million for Q1 2026 at Beta Bionics, down from $328.7 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $338.0 million in Q1 2025 to a low of $110.0 million in Q4 2023.
• A 4-year average of $270.1 million and a median of $328.7 million in 2025 frame the typical range for Liabilities and Shareholders Equity.
• Across the five-year window, Liabilities and Shareholders Equity surged 119.68% in 2025 and declined 9.94% in 2026, its largest moves.
• Beta Bionics' Liabilities and Shareholders Equity stood at $110.0 million in 2023, then jumped by 35.99% to $149.6 million in 2024, then soared by 119.68% to $328.7 million in 2025, then fell by 7.4% to $304.4 million in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $304.4 million, $328.7 million, and $330.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison